Background: Our understanding of HIV-1 and antiretroviral treatment (ART) is strongly biased towards subtype B, the predominant subtype in North America and western Europe. Efforts to characterize the response to first-line treatments in other HIV-1 subtypes have been hindered by the availability of large study cohorts in resource-limited settings. To maximize our statistical power, we combined HIV-1 sequence and clinical data from every available study population associated with the Joint Clinical Research Centre (JCRC) in Uganda. These records were combined with contemporaneous ART-naive records from Uganda in the Stanford HIVdb database.
Background
East Africa was one of the first regions in the world to experience high rates of HIV infection [1] . In 1990, for instance, some antenatal clinics in Uganda recorded adult HIV prevalences among women exceeding 30% [2] . Currently, the adult prevalence of HIV in Uganda is about 7.1% [3] . Increasing the coverage of combination antiretroviral therapy in Uganda is a crucial public health objective to not only reduce HIV-related morbidity and mortality, but also to prevent the onward transmission of HIV by reducing plasma viral loads [4, 5] . However, the enormous genetic diversity of the HIV-1 subtypes has been a persistent concern for antiretroviral treatment, especially in low-and middle-income countries like Uganda with multiple prevalent subtypes [6] . Antiretroviral drugs have generally been developed and tested on HIV subtype B [7] , which is the predominant subtype in North America and western Europe [8] . HIV-1 infections in Uganda are predominated by subtypes A and D [9] , with a low frequency of subtype C that is the predominant subtype in southern Africa. In addition, recombinants of subtypes A and D have historically been observed in about 10% to 30% of HIV infections sampled in Uganda [10, 11] . Based on a phylogenetic analysis of dated HIV sequences, subtype A likely migrated into Uganda around the 1950s before subtype D entered about a decade afterwards [12] . To date, subtype A HIV-1 infections are more prevalent in the east and north regions of Uganda, while subtype D dominates in the west and south of this small country [13] .
There is accumulating evidence of clinically-significant differences among the HIV-1 subtypes. For example, multiple studies have observed that subtype D is associated with a faster rate of disease progression relative to subtype A in the absence of treatment [14] [15] [16] . Our previous 15-year natural history study of HIV disease progression confirmed these observations, but also described a significantly slower rate of disease progression in subtype C HIV-1 infected individuals over those infected with subtype A or D [16, 17] . Previous studies of serodiscordant couples have also reported that subtype D has a lower transmission rate than subtype A [18] , which is consistent with a decline in the overall prevalence of subtype D in the region [19] . In addition, HIV subtype variation can have an impact on the emergence of drug resistance mutations. For example, the HIV-1 RT mutation K65R emerges more rapidly in subtype C infections due to variation among subtypes in a homopolymeric region that interrupts reverse transcription and induces a higher rate of base misincorporation [20] .
Evaluating the clinical significance of HIV non-B subtypes in the context of antiretroviral treatment (ART) remains a significant challenge and few studies have the necessary sample sizes in resource-limited settings, let alone in any specific region. In a recent systematic review of switching to second-line treatments in sub-Saharan Africa [21] , the estimated incidence averaged about 2.6 first-line treatment failures per 100 personyears and ranged between 2 to 5 per 100 person-years. Consequently, prospectively enrolling patients on firstline treatment can severely limit the expected number of treatment failures in the sample population. In this study, we have combined HIV sequence and clinical data associated with first-line treatment failures from multiple study cohorts and clinical sites based in Uganda ( n = 1724 ). These data were supplemented with drug-naive (baseline) HIV sequence data from the same clinical sites ( n = 968 ) and location-time matched records from the Stanford HIV drug resistance database ( n = 1462 ) [22] for a combined total of 4154 patient records. To date, this represents the largest retrospective multi-site analysis of HIV first-line treatment failures in Uganda, and likely in all of sub-Saharan Africa. The primary objective of our study was to assess the clinical significance of HIV-1 subtypes in the context of first-line treatment failure. Results from our investigation then motivated a deeper analysis on the impact of frequent inter-subtype recombination in this region where both subtypes A and D are prevalent.
Here we report evidence that first-line treatment failure in Uganda is generally more strongly associated with drug regimens than HIV-1 subtypes. By expanding our database, however, we observe that A/D recombinants are significantly less associated with first-line treatment failure, and that this effect is more pronounced with an increasing number of putative recombination breakpoints in HIV-1 pol.
Methods

Data collection
Anonymized HIV genotypes and clinical data records were collected from multiple clinical sites and cohort studies (Additional file 1: Table S1 ). Samples from the Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) trial [23] were collected under a protocol approved by the research ethics committee at University College London, with written informed consent provided by patients, or by caregivers for patients under 18 years of age. The sample collection protocol for the Hormonal Contraception and HIV-1 Genital Shedding and Disease Progression among Women with Primary HIV Infection (GS) study [16, 24] was approved by the institutional review boards of the collaborating institutions, and all participants provided informed consent. Samples from the Pan-African Studies to Evaluate Resistance (2008, PASER) network [25] were collected under a protocol approved by research ethics committees at the collaborating sites and the Academic Medical Center (AMC) of the University of Amsterdam, and all participants provided written informed consent. Samples from the Joint Clinical Research Centre (JCRC), the main HIV care provider in Uganda, included patient samples from the JCRC clinics (2005-2016, DR) and the Monitoring Antiretroviral Resistance in Children (2010-2011, MARCH) observational cohort study [26] with informed consent provided by parent(s)/guardian(s); the sample collection protocol was approved by the ethical committees at the JCRC and the AMC. Our analysis of these anonymized data was collectively approved by the institutional review board of the JCRC (EM10-07).
Samples collected in countries other than Uganda (e.g., Zimbabwe, Malawi) were excluded from further analyses. First-line treatment failures were defined by the presence of an HIV drug resistance genotype record in the database subsequent to start of treatment, which implied a detectable viral load ( > 50 copies/mL plasma). Drug exposures were recorded as the drug regimen at the start of treatment for baseline samples, and the regimen at the time of virological failure otherwise. The median collection year of samples was 2010, with the earliest sample collected in 2005 and the most recent in 2016; this study was initiated in August 2016.
Data processing
We used a rules-based record linkage algorithm to associate these sequence-derived data to clinical variables in a separate database, with a customized rule set for the sequence/patient label nomenclature of each study population. This record linkage was determined to be a necessary processing step when initial analyses found discordant patient identifiers between databases that were likely the result of errors during manual data entry. The clinical data included cohort study, region, gender, age at enrollment, plasma viral load and CD4 cell count at baseline, and first-line ART regimen. To augment the number of baseline samples in the data, we merged the sequence database with the genotype-treatment correlation dataset published by the Stanford HIVdb database [22] , which we reduced to only drug-naive records collected in Uganda ( n = 1462 ). Note that our linkage algorithm was applied only to anonymized data collected from clinical sites and cohort studies associated with the JCRC; no linkage was applied to any data from the Stanford database. Since the Stanford HIVdb records spanned a broader range of sample collection dates, we excluded all HIVdb records that were sampled prior to 2005 to ensure that the HIVdb sequences were contemporaneous with samples from our multi-cohort study. We verified that none of the HIVdb sequences duplicated records in the JCRC database. Resistance predictions for HIV sequences were generated with the Stanford HIVdb algorithm [22] . Subtype predictions from nucleotide sequences were obtained using SCUEAL [27] and verified with REGA (version 3.0) [28] and by phylogenetic reconstruction. Complete details on the sequence analysis methods are provided as Additional file 1: Text S1.
Statistical analysis
All statistical analyses, including generalized linear models (GLMs), were performed in the R computing environment unless noted otherwise. Associations between categorical variables were evaluated using Fisher's exact tests. We used a log-transformation of plasma viral loads and a cubic root transformation of CD4 cell counts to accommodate the normality assumption of parametric tests. To fit GLMs to the genotypic susceptibility score (GSS) data [29] , which are calculated to a resolution of 0.25 units, we rounded these outcomes to the nearest integer and used a binomial logit-link function. Statistical tests were generally reported by 95% confidence intervals; in cases where we reported P-values, significance was interpreted at a threshold of α = 0.05 unless otherwise noted. Cases with missing data were dropped from the respective analyses. A Bayesian network analysis was performed using a custom implementation in HyPhy [30] (see Additional file 1: Text S2).
Results
Subtype distribution
We identified 968 baseline and 1724 first-line treatment failures from the Ugandan study populations, and an additional 1462 drug-naïve samples from Uganda in the Stanford HIVdb database for a total of 4154 samples (Table 1 ). This sample size is predicted to have sufficient power to detect an association between treatment failure and subtype at an odds ratio of ∼1.2 or greater, given an overall 5% prevalence of failure and a subtype frequency of 20% (Additional file 1: Figure S1 ). Figure 1 displays the distribution of HIV-1 subtypes across regions of Uganda. Overall, HIV-1 subtype A was the most prevalent in our database (43%), followed by subtype D (30%). We also observed a greater frequency of A/D recombinants (7%) than subtype C (3%). About 17% of sequences received 'other' subtype/recombinant classifications; the most common variants within this category were unclassified subtype U ( n = 116 ) and A1/U recombinants ( n = 100 ). In our subsequent phylogenetic analysis (Additional file 1: Figure S2 ), subtype U sequences and sequence fragments were placed within or adjacent to the subtype A subtree; hence, they may represent subtype A lineages that are distinct from the subtype reference sequences. We retained the original subtype assignments for the remainder of our analyses. The proportionate agreement between the SCUEAL and REGA algorithms in assigning subtype A, C and D and A/D recombinants was 96.4% (Cohen's κ = 0.94 ; Additional file 1: Table S2 ).
Treatment failure and drug resistance
We observed significant regional differences in drug exposure: for example, 3TC was more frequently prescribed in Kampala than other regions (Fisher's exact test, odds ratio OR = 2.45 , 95% CI = [1.95, 3.07]) and EFV was prescribed less frequently ( OR = 0.61 [0.50, 0.75]). To evaluate whether drug resistance patterns were consistent with treatment failures, we calculated the genotypic susceptibility score (GSS) for each individual with a known drug regimen ( n = 2012). The GSS can be interpreted as the number of effective drugs in an individual's regimen, given the genetic makeup of their virus population [29] , where drug effectiveness is based on the Stanford HIVdb resistance score. The mean GSS among failure samples (0.77) was significantly lower than the mean among baseline samples (2.71; binomial GLM Table 1 Summary table for HIV-1 Fig. 2 ), which was consistent with the virus populations accumulating resistance mutations in response to each patient's drug regimen. We found no significant effect of subtype on GSS when this term was added to the model, which implied that patterns of drug resistance in treatment failures were similar across subtypes. Next, we used Markov chain Monte Carlo sampling to fit a Bayesian network model [31] with baseline/failure as a binomial variable to evaluate associations between specific drugs and treatment failure, while accommodating for potential subtype differences, geographic regional differences, and drugs employed in combination therapy ( Fig. 3) . Convergence between replicate chain samples was accessed with respect to posterior probability using the Gelman-Rubin diagnostic (upper confidence limit = 1.01). The model was fit to the subset of records with complete information about sampling region, subtype classification and drug exposures ( n = 1750 ). Of this subset, n = 721 represented baseline records and n = 1029 represented treatment failures ( Table 1 ). The distribution of edges among nodes representing antiretroviral drugs was consistent with common drug combinations. For example, we obtained well-supported edges connecting the nodes representing the drugs 3TC, AZT and NVP. Our network model suggests that, once regional differences and drug combinations were accounted for, only 3TC was positively associated with treatment failure (marginal posterior probability, MPP = 0.95 ). Similarly, the model predicted that AZT and TDF were negatively associated with failures (both MPP = 0.91 ). Our consensus Bayesian network did not detect any significant associations between HIV-1 subtypes and any other variables in the network, including first-line treatment failures (Fig. 3 ). This result indicated that any statistical association between first-line treatment failure and HIV-1 subtypes was overwhelmed by the effects of drug exposures. Overall, when accounting for subtype, regional sites in Uganda, and drug regimens, the most significant correlate of first line treatment failure appeared to be the use of 3TC. These results imply that associations between HIV-1 subtypes and first-line treatment failure, if any, were not driven by drug exposure or resistance.
baseline and treatment failure samples
Clinical differences among HIV-1 subtypes
Plasma viral load (pVL) measurements were available for 579 baseline samples and 962 failure samples. The mean difference in pVL between baseline and failures samples was 0.44 log 10 units, and statistically significant ( Table 1 ). There was not significant variation in log 10 pVL among subtypes at baseline (ANOVA, P = 0.85 ), but marginally significant variation in failure samples ( P = 0.04 ; Additional file 1: Figure S3 ). Within treatment failures, individuals with subtype C infections tended to have lower pVL than the other subtypes (mean difference = − 0.38 log 10 units; Student's t test, 95% CI = [ − 0.75 , − 0.02]); this result is consistent with previous work in this population [16] . CD4 cell counts were only available for 141 failure samples, and no counts were available for baseline samples (Table 1) . We observed no significant variation in CD4 among subtypes (ANOVA, P = 0.09). Table 1 and Additional file 1: Figure S4 depict the overall distribution of HIV-1 subtypes between baseline and failure samples in the entire database ( n = 4154 ). We found that SCUEAL-defined A/D recombinants ( n = 302 ) were significantly less frequent in failure samples (Fisher's exact test, odds ratio OR = 0.53 , 95% CI = [0.40, 0.69]). A similar association was obtained with REGA-defined A/D recombinants ( n = 284 , OR = 0.34 [0.25, 0.46]); for brevity, the remainder of our analysis will utilize the SCUEAL predictions. To assess whether this effect was caused by combining the Uganda clinical and study population data with published sequences from the Stanford HIVdb database, we repeated our analysis excluding the HIVdb data. The frequency of A/D recombinants remained significantly lower among failure samples in this reduced data set ( OR = 0.58 [0.41, 0.80]). We also observed that sequences classified by SCUEAL into the 'other' category, which comprises subtype U (unclassified) and inter-subtype recombinants other than A/D, were significantly more likely to occur in failure samples ( OR = 1.3 [1.07, 1.49]; Additional file 1: Figure S4 ). However, the reproducibility of classifying sequences into the 'other' category was low (Additional file 1: Table S2 ). Unexpectedly, subtype U sequences alone were significantly more frequent among failure samples ( OR = 2.0 [1.38, 3.03]); no such association was observed for sequences categorized as subtype A ( OR = 1.07 [0.94, 1.21]). Thus, although the subtype U sequences appear to be evolutionarily related to subtype A (Additional file 1: Figure S2 ), our data suggest that these unclassified variants may be associated with increased rates of first-line treatment failure. The number of inferred breakpoints in A/D recombinants was significantly negatively associated with firstline treatment failures (binomial GLM effect estimate = − 0.39 [ − 0.67 , − 0.12 ] log odds per breakpoint). For instance, HIV-1 sequences with more than two recombination breakpoints were about 60% less likely to appear in failure samples than expected by chance. This effect was not influenced by sequence length (likelihood-ratio test, P = 0.94 ). We also found that the number of breakpoints remained significantly lower in failure samples when we expanded our analysis to the entire database including non-recombinants and other inter-subtype recombinants. Since this distribution included a large class of zero breakpoints, we fit a zero-inflated Poisson model to these counts [32] . We found that treatment failures had a significantly greater chance of carrying a nonrecombinant strain (log odds = + 0.16 , 95% CI = [0.02, 0.31]) and a significantly reduced number of breakpoints when carrying a recombinant strain (log odds = − 0.12 , [ − 0.2 , − 0.03 ]; Table 1 ).
Fewer recombinants among treatment failures
Since we found a significantly lower frequency of A/D recombinants in the sample population of first-line treatment failures, we further examined associations between HIV-1 recombination and treatment failures. First, we visualized the distribution of inferred recombination breakpoints and assignments of recombinant fragments to HIV-1 subtypes A and D (Additional file 1: Figure S5 ). This plot implies a complex evolutionary history of A/D recombinants in Uganda, with recombinants arising from multiple events. Next we examined whether particular A/D recombinant fragments were more associated with first-line treatment failures using a series of nucleotide-level association tests along the length of the HIV-1 pol sequence. This analysis revealed that associations between subtype A-derived fragments and treatment failures tended to cluster towards the 3′end/C-terminus of RT, just downstream of the resistance associated sites in RT ( Fig. 4) . Circles were coloured with respect to the P-value of each test (see inset legend). To avoid cluttering the plot, we thinned the number of tests to regular intervals of four nucleotides
